Significance: The number of kidney cancers is growing 3–5% each year due to unknown etiologies. Intra- and inter-tumor mediators increase oxidative stress and drive tumor heterogeneity. Recent Advances: Technology advancement in state-of-the-art instrumentation and methodologies allows researchers to detect and characterize global landscaping modifications in genes, proteins, and pathophysiology patterns at the single-cell level. Critical Issues: We postulate that the sources of reactive oxygen species (ROS) and their activation within subcellular compartments will change over a timeline of tumor evolvement and contribute to tumor heterogeneity. Therefore, the complexity of intracellular changes within a tumor and ROS-induced tumor heterogeneity coupled to the advancement of detecting these events globally are limited at the level of data collection, organization, and interpretation using software algorithms and bioinformatics. Future Directions: Integrative and collaborative research, combining the power of numbers with careful experimental design, protocol development, and data interpretation, will translate cancer biology and therapeutics to a heightened level or leave the abundant raw data as stagnant and underutilized. Antioxid. Redox Signal. 25, 685–701.
Get full access to this article
View all access options for this article.
References
1.
AbenteEJ, SubramanianM, RamachandranV, and Najafi-ShoushtariSH. MicroRNAs in obesity-associated disorders. Arch Biochem Biophys, 589: 108–119, 2016.
2.
AggarwalBB, VijayalekshmiRV, and SungB. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res, 15: 425–430, 2009.
3.
AraiE and KanaiY. Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol, 4: 58–73, 2010.
4.
BandieraS, CartaultF, JannotAS, HatemE, GirardM, RifaiL, LoiseauC, MunnichA, LyonnetS, and Henrion-CaudeA. Genetic variations creating microRNA target sites in the FXN 3′-UTR affect frataxin expression in Friedreich ataxia. PLoS One, 8: e54791, 2013.
5.
BandieraS, MatégotR, GirardM, DemongeotJ, and Henrion-CaudeA. MitomiRs delineating the intracellular localization of microRNAs at mitochondria. Free Radic Biol Med, 64: 12–19, 2013.
6.
BánfiB, MalgrangeB, KniszJ, StegerK, Dubois-DauphinM, and KrauseKH. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem, 279: 46065–46072, 2004.
7.
BedardK and KrauseKH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev, 87: 245–313, 2007.
8.
BerndtJD, MoonRT, and MajorMB. Beta-catenin gets jaded and von Hippel-Lindau is to blame. Trends Biochem Sci, 34: 101–104, 2009.
9.
Bienertova-VaskuJ, SanaJ, and SlabyO. The role of microRNAs in mitochondria in cancer. Cancer Lett, 336: 1–7, 2013.
10.
BlockK. Emerging Research and Treatments in Renal Cell Carcinoma. Rijeka, Croatia: In Tech, 2012, p. 137.
11.
BlockK and GorinY. Aiding and abetting roles of NOX oxidases in cellular transformation. Nat Rev Cancer, 12: 627–637, 2012.
12.
BlockK, GorinY, and AbboudHE. Subcellular localization of NOX4 and regulation in diabetes. Proc Natl Acad Sci U S A, 106: 14385–14390, 2009.
BlockK, GorinY, NewDD, EidA, ChelmickiT, ReedA, ChoudhuryGG, ParekhDJ, and AbboudHE. The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin. Am J Pathol, 176: 2447–2455, 2010.
15.
BlowerPE, VerducciJS, LinS, ZhouJ, ChungJH, DaiZ, LiuCG, ReinholdW, LorenziPL, KaldjianEP, CroceCM, WeinsteinJN, and SadeeW. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther, 6: 1483–1491, 2007.
16.
BonnerMY and ArbiserJL. The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer. Future Med Chem, 6: 1413–1422, 2014.
17.
BoströmAK, LindgrenD, JohanssonME, and AxelsonH. Effects of TGF-β signaling in clear cell renal cell carcinoma cells. Biochem Biophys Res Commun, 435: 126–133, 2013.
18.
BoudreauHE, CasterlineBW, RadaB, KorzeniowskaA, and LetoTL. Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic Biol Med, 53: 1489–1499, 2012.
19.
BrewerAC, MurrayTV, ArnoM, ZhangM, AnilkumarNP, MannGE, and ShahAM. Nox4 regulates Nrf2 and glutathione redox in cardiomyocytes in vivo. Free Radic Biol Med, 51: 205–215, 2011.
20.
BrunelleJK, BellEL, QuesadaNM, VercauterenK, TirantiV, ZevianiM, ScarpullaRC, and ChandelNS. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab, 1: 409–414, 2005.
21.
BussolatiB, BrunoS, GrangeC, FerrandoU, and CamussiG. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J, 22: 3696–3705, 2008.
22.
CadenasE and DaviesKJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med, 29: 222–230, 2000.
23.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 499: 43–49, 2013.
24.
CarnethonMR, De ChavezPJ, BiggsML, et al.Association of weight status with mortality in adults with incident diabetes. JAMA, 308: 581–590, 2012.
25.
CattoJW, AlcarazA, BjartellAS, De Vere WhiteR, EvansCP, FusselS, HamdyFC, KallioniemiO, MengualL, SchlommT, and VisakorpiT. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol, 59: 671–681, 2011.
26.
ChandelNS, McClintockDS, FelicianoCE, WoodTM, MelendezJA, RodriguezAM, and SchumackerPT. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem, 275: 25130–25138, 2000.
27.
ChandelNS, Vander HeidenMG, ThompsonCB, and SchumackerPT. Redox regulation of p53 during hypoxia. Oncogene, 19: 3840–3848, 2000.
28.
ChenJ, ZhangD, ZhangW, TangY, YanW, GuoL, and ShenB. Clear cell renal cell carcinoma associated microRNA expression signatures identified by an integrated bioinformatics analysis. J Transl Med, 11: 169, 2013.
29.
ChengG, CaoZ, XuX, van MeirEG, and LambethJD. Homologs of gp91phox: cloning and tissue expression of NOX3, NOX4, and NOX5. Gene, 269: 131–140, 2001.
30.
ChengG and LambethJD. NOXO1, regulation of lipid binding, localization, and activation of NOX1 by the Phox homology (PX) domain. J Biol Chem, 279: 4737–4742, 2004.
31.
ChitaliaVC, FoyRL, BachschmidMM, ZengL, PanchenkoMV, ZhouMI, BhartiA, SeldinDC, LeckerSH, DominguezI, and CohenHT. Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol, 10: 1208–1216, 2008.
32.
ChowTF, MankaruosM, ScorilasA, YoussefY, GirgisA, MossadS, MetiasS, RofaelY, HoneyRJ, StewartR, PaceKT, and YousefGM. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol, 183: 743–751, 2010.
33.
ChristensenEI, BirnH, RippeB, and MaunsbachAB. Controversies in nephrology: renal albumin handling, facts, and artifacts!. Kidney Int, 72: 1192–1194, 2007.
34.
Clavijo-CornejoD, Enriquez-CortinaC, López-ReyesA, Domínguez-PérezM, NuñoN, Domínguez-MerazM, BucioL, SouzaV, FactorVM, ThorgeirssonSS, Gutiérrez-RuizMC, and Gómez-QuirozLE. Biphasic regulation of the NADPH oxidase by HGF/c-Met signaling pathway in primary mouse hepatocytes. Biochimie, 95: 1177–1184, 2013.
35.
CucoranuI, ClempusR, DikalovaA, PhelanPJ, AriyanS, DikalovS, and SorescuD. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res, 97: 900–907, 2005.
DeyN, DasF, Ghosh-ChoudhuryN, MandalCC, ParekhDJ, BlockK, KasinathBS, AbboudHE, and ChoudhuryGG. microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. PLoS One, 7: e37366, 2012.
38.
DieboldI, PetryA, HessJ, and GörlachA. The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1. Mol Biol Cell, 21: 2087–2096, 2010.
39.
DrabkinHA and GemmillRM. Cholesterol and the development of clear-cell renal carcinoma. Curr Opin Pharmacol, 12: 742–750, 2012.
40.
DuarteFV, PalmeiraCM, and RoloAP. The Role of microRNAs in mitochondria: small players acting wide. Genes, 5: 865–886, 2014.
41.
DupuyC, OhayonR, ValentA, Noël-HudsonMS, DèmeD, and VirionA. Purification of a novel flavoprotein involved in the thyroid NADPH oxidase. Cloning of the porcine and human cdnas. J Biol Chem, 274: 37265–37269, 1999.
42.
EllisL, AtadjaPW, and JohnstoneRW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther, 8: 1409–1420, 2009.
43.
FérailleE, DizinE, RothI, DerouetteJP, SzantoI, MartinPY, de SeigneuxS, and HaslerU. NADPH oxidase 4 deficiency reduces aquaporin-2 mRNA expression in cultured renal collecting duct principal cells via increased PDE3 and PDE4 activity. PLoS One, 9: e87239, 2014.
44.
FitzgeraldJP, NayakB, ShanmugasundaramK, FriedrichsW, SudarshanS, EidAA, DeNapoliT, ParekhDJ, GorinY, and BlockK. NOX4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production. PLoS One, 7: e30712, 2012.
45.
FuY, ZhangY, WangZ, WangL, WeiX, ZhangB, WenZ, FangH, PangQ, and YiF. Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am J Nephrol, 32: 581–589, 2010.
46.
GalleggianteV, RutiglianoM, SallustioF, RibattiD, DitonnoP, BettocchiC, SelvaggiFP, LucarelliG, and BattagliaM. CTR2 identifies a population of cancer cells with stem cell-like features in patients with clear cell renal cell carcinoma. J Urol, 192: 1831–1841, 2014.
47.
GantiS, TaylorSL, KimK, HoppelCL, GuoL, YangJ, EvansC, and WeissRH. Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer, 130: 2791–2800, 2012.
GeisztM. NADPH oxidases: new kids on the block. Cardiovasc Res, 1: 289–299, 2006.
50.
GeisztM, KoppJB, VárnaiP, and LetoTL. Identification of reNOX, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A, 97: 8010–8014, 2000.
51.
GnarraJR, ToryK, WengY, SchmidtL, WeiMH, LiH, LatifF, LiuS, ChenF, DuhFM, LubenskyI, DuanDR, FlorenceC, PozzattiR, WaltherMM, BanderNH, GrossmanHB, BrauchH, PomerS, BrooksJD, IsaacsWB, LermanMI, ZbarB, and LinehanWM. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet, 7: 85–90, 1994.
52.
GoochJL, TangY, RiconoJM, and AbboudHE. Insulin-like growth factor-I induces renal cell hypertrophy via a calcineurin-dependent mechanism. J Biol Chem, 276: 42492–42500, 2001.
53.
GordilloGM, BiswasA, KhannaS, PanX, SinhaM, RoyS, and SenCK. Dicer knockdown inhibits endothelial cell tumor growth via microRNA 21a-3p targeting of NOX-4. J Biol Chem, 289: 9027–9038, 2014.
54.
GorinY, BlockK, HernandezJ, BhandariB, WagnerB, BarnesJL, and AbboudHE. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem, 280: 39616–39626, 2005.
55.
GowrishankarB, IbragimovaI, ZhouY, SlifkerMJ, DevarajanK, Al-SaleemT, UzzoRG, and CairnsP. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther, 15: 329–341, 2014.
56.
GoyalP, WeissmannN, GrimmingerF, HegelC, BaderL, RoseF, FinkL, GhofraniHA, SchermulyRT, SchmidtHH, SeegerW, and HänzeJ. Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic Biol Med, 36: 1279–1288, 2004.
57.
GrangeC, CollinoF, TapparoM, and CamussiG. Oncogenic micro-RNAs and renal cell carcinoma. Front Oncol, 4: 49, 2014.
58.
GreggJL, TurnerRM2nd, ChangG, JoshiD, ZhanY, ChenL, and MaranchieJK. NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2α. Cancer Res, 74: 3501–3511, 2014.
59.
GuanY and BreyerMD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int, 60: 14–30, 2001.
60.
GuzyRD, HoyosB, RobinE, ChenH, LiuL, MansfieldKD, SimonMC, HammerlingU, and SchumackerPT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab, 1: 401–408, 2005.
61.
HakimiAA, FurbergH, ZaborEC, JacobsenA, SchultzN, CirielloG, MikklineniN, FiegoliB, KimPH, VossMH, ShenH, LairdPW, SanderC, ReuterVE, MotzerRJ, HsiehJJ, and RussoP. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst, 105: 1862–1870, 2013.
62.
HakimiAA, ReznikE, LeeCH, CreightonCJ, BrannonAR, LunaA, AksoyBA, LiuEM, ShenR, LeeW, ChenY, StirdivantSM, RussoP, ChenYB, TickooSK, ReuterVE, ChengEH, SanderC, and HsiehJJ. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell, 29: 104–116, 2016.
63.
HaleLJ and CowardRJ. Insulin signalling to the kidney in health and disease. Clin Sci (Lond). 124: 351–370, 2013.
64.
HalliwellB, ZhaoK, and WhitemanM. Nitric oxide and peroxynitrite. The ugly, the uglier and the not so good: a personal view of recent controversies. Free Radic Res, 31: 651–669, 1999.
65.
Harb-de la RosaA, AckerM, KumarRA, and ManoharanM. Epigenetics application in the diagnosis and treatment of bladder cancer. Can J Urol, 22: 7947–7951, 2015.
66.
HeinzelmannJ, HenningB, SanjmyatavJ, PosorskiN, SteinerT, WunderlichH, GajdaMR, and JunkerK. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol, 29: 367–373, 2011.
67.
HermanJG, LatifF, WengY, LermanMI, ZbarB, LiuS, SamidD, DuanDS, GnarraJR, LinehanWM, and BaylinS. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A, 91: 9700–9704, 1994.
68.
HigginsJP, ShinghalR, GillH, ReeseJH, TerrisM, CohenRJ, FeroM, PollackJR, van de RijnM, and BrooksJD. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol, 162: 925–932, 2003.
69.
HiragaR, KatoM, MiyagawaS, and KamataT. Nox4-derived ROS signaling contributes to TGF-β-induced epithelial-mesenchymal transition in pancreatic cancer cells. Anticancer Res, 33: 4431–4438, 2013.
70.
HitchlerMJ and DomannFE. Redox regulation of the epigenetic landscape in cancer: a role for metabolic reprogramming in remodeling the epigenome. Free Radic Biol Med, 53: 2178–2187, 2012.
71.
HodgkinsonCP, KangMH, Dal-PraS, MirotsouM, and DzauVJ. MicroRNAs and cardiac regeneration. Circ Res, 116: 1700–1171, 2015.
72.
HuCJ, WangLY, ChodoshLA, KeithB, and SimonMC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol, 23: 9361–9374, 2003.
73.
HuT, RamachandraraoSP, SivaS, ValanciusC, ZhuY, MahadevK, TohI, and GoldsteinBJ, WoolkalisM, and SharmaK. Reactive oxygen species production via NADPH oxidase mediates TGF-beta-induced cytoskeletal alterations in endothelial cells. Am J Physiol Renal Physiol, 289: F816–F825, 2005.
74.
HuangJ, YaoX, ZhangJ, DongB, ChenQ, XueW, LiuD, and HuangY. Hypoxia-induced downregulation of miR-30c promotes epithelial-mesenchymal transition in human renal cell carcinoma. Cancer Sci, 104: 1609–1617, 2013.
75.
IsaacsWB, LermanMI, ZbarB, and LinehanWM. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet, 7: 85–90, 1994.
76.
Kalantar-ZadehK, StrejaE, KovesdyCP, et al.The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc, 85: 991–1001, 2010.
77.
KawakamiK, HirataH, YamamuraS, KikunoN, SainiS, MajidS, TanakaY, KawamotoK, EnokidaH, NakagawaM, and DahiyaR. Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res, 69: 8603–8610, 2009.
78.
KhanMI, CzarneckaAM, HelbrechtI, BartnikE, LianF, and SzczylikC. Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. Stem Cell Res Ther, 6: 178, 2015, 2015.
79.
KimK, TaylorSL, GantiS, GuoL, OsierMV, and WeissRH. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS, 15: 293–303, 2011.
80.
KimWJ, GerseyZ, and DaakaY. Rap1GAP regulates renal cell carcinoma invasion. Cancer Lett, 320: 65–71, 2012.
81.
KimY and KimVN. MicroRNA factory: RISC assembly from precursor microRNAs. Mol Cell, 46: 384–386, 2012.
82.
KluzekS, NewtonJL, and ArdenNK. Osteoarthritis a metabolic disorder?. Br Med Bull, 115: 111–121, 2015.
83.
KondoK, KlcoJ, NakamuraE, LechpammerM, and KaelinWGJr.Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell, 1: 237–246, 2002.
KurbanG, HudonV, DuplanE, OhhM, and PauseA. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res, 66: 1313–1319, 2006.
86.
LambethJD. NOX enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med, 43: 332–347, 2007.
87.
LassègueB and GriendlingKK. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol, 30: 653–661, 2010.
88.
LiJ and LamM. Registered report: the microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Reproducibility project: Cancer biology. Elife, 4: e06434, 2015.
89.
LiJ, WangE, DuttaS, LauJS, JiangSW, DattaK, and MukhopadhyayD. Protein kinase C-mediated modulation of FIH-1 expression by the homeodomain protein CDP/Cut/Cux. Mol Cell Biol, 27: 7345–7353, 2007.
90.
LiangJ, ZhangY, JiangG, LiuZ, XiangW, ChenX, ChenZ, and ZhaoJ. MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res, 21: 83–91, 2013.
91.
LiuQ, JinJ, YingJ, SunM, CuiY, ZhangL, XuB, FanY, and ZhangQ. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma. Int J Mol Sci, 16: 10636–10649, 2015.
92.
LustgartenMS, BhattacharyaA, MullerFL, JangYC, ShimizuT, ShirasawaT, RichardsonA, and Van RemmenH. Complex I generated, mitochondrial matrix-directed superoxide is released from the mitochondria through voltage dependent anion channels. Biochem Biophys Res Commun, 422: 515–521, 2012.
93.
LvL, HuangF, MaoH, LiM, LiX, YangM, and YuX. MicroRNA-21 is overexpressed in renal cell carcinoma. Int J Biol Markers, 28: 201–207, 2013.
94.
MaJ, DongC, and JiC. MicroRNA and drug resistance. Cancer Gene Ther, 17: 523–531, 2010.
95.
MagentaA, GrecoS, GaetanoC, and MartelliF. Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci, 14: 17319–17346, 2013.
96.
MaloufGG, ZhangJ, YuanY, CompératE, RouprêtM, CussenotO, ChenY, ThompsonEJ, TannirNM, WeinsteinJN, ValeroV, KhayatD, SpanoJP, and SuX. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol, 9: 32–43, 2015.
97.
MariappanMM, FeliersD, MummidiS, ChoudhuryGG, and KasinathBS. High glucose, high insulin, and their combination rapidly induce laminin-beta1 synthesis by regulation of mRNA translation in renal epithelial cells. Diabetes, 56: 476–485, 2007.
98.
MarinT, GongolB, ChenZ, WooB, SubramaniamS, ChienS, and ShyyJY. Mechanosensitive microRNAs-role in endothelial responses to shear stress and redox state. Free Radic Biol Med, 64: 61–68, 2013.
99.
MaxwellPH, DachsGU, GleadleJM, NichollsLG, HarrisAL, StratfordIJ, HankinsonO, PughCW, and RatcliffePJ. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A, 94: 8104–8109, 1997.
100.
MayrJA, MeierhoferD, ZimmermannF, FeichtingerR, KöglerC, RatschekM, SchmellerN, SperlW, and KoflerB. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res, 14: 2270–2275, 2008.
101.
MengH, ChenG, GaoHM, SongX, ShiY, and CaoL. The emerging nexus of active DNA demethylation and mitochondrial oxidative metabolism in post-mitotic neurons. Int J Mol Sci, 15: 22604–22625, 2014.
102.
MittalM, RothM, KönigP, HofmannS, DonyE, GoyalP, SelbitzAC, SchermulyRT, GhofraniHA, KwapiszewskaG, KummerW, KlepetkoW, HodaMA, FinkL, HänzeJ, SeegerW, GrimmingerF, SchmidtHH, and WeissmannN. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res, 101: 258–267, 2007.
103.
MoestrupSK and NielsenLB. The role of the kidney in lipid metabolism. Curr Opin Lipidol, 16: 301–306, 2005.
104.
MorenoSM, BenítezIA, and Martínez GonzálezMA. Ultrastructural studies in a series of 18 cases of chromophobe renal cell carcinoma. Ultrastruct Pathol, 29: 377–387, 2005.
105.
MorrisMR, RickettsC, GentleD, AbdulrahmanM, ClarkeN, BrownM, KishidaT, YaoM, LatifF, and MaherER. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene, 29: 2104–2117, 2010.
106.
MullerFL, LiuY, and Van RemmenH. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem, 279: 49064–49073, 2004.
107.
MüllerS and NowakK. Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. Biomed Res Int. 948408, 2014.
108.
MunariE, MarchionniL, ChitreA, HayashiM, MartignoniG, BrunelliM, GobboS, ArganiP, AllafM, HoqueMO, and NettoGJ. Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Hum Pathol, 45: 1130–1138, 2014.
109.
MunsonJM, FriedL, RowsonSA, BonnerMY, KarumbaiahL, DiazB, CourtneidgeSA, KnausUG, BratDJ, ArbiserJL, and BellamkondaRV. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci Transl Med, 4: 127ra36, 2012.
110.
NakadaC, MatsuuraK, TsukamotoY, TanigawaM, YoshimotoT, NarimatsuT, NguyenLT, HijiyaN, UchidaT, SatoF, MimataH, SetoM, and MoriyamaM. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol, 216: 418–427, 2008.
111.
NayakBK, FeliersD, SudarshanS, FriedrichsWE, DayRT, NewDD, FitzgeraldJP, EidA, DenapoliT, ParekhDJ, GorinY, and BlockK. Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translation. Oncogene, 32: 3147–3155, 2013.
112.
NewDD, BlockK, BhandhariB, GorinY, and AbboudHE. GF-I increases the expression of fibronectin by NOX4-dependent Akt phosphorylation in renal tubular epithelial cells. Am J Physiol Cell Physiol, 302: C122–C130, 2012.
113.
NielsenSF, NordestgaardBG, and BojesenSE. Statin use and reduced cancer-related mortality. N Engl J Med, 367: 1792–802, 2012.
114.
NingB, LiW, ZhaoW, and WangR. Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin, 48: 97–109, 2015.
115.
OshimoriN, OristianD, and FuchsE. TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell, 160: 963–976, 2015.
116.
PanchenkoMV, ZhouMI, and CohenHT. von Hippel-Lindau partner Jade-1 is a transcriptional co-activator associated with histone acetyltransferase activity. J Biol Chem, 279: 56032–56041, 2004.
117.
PetilloD, KortEJ, AnemaJ, FurgeKA, YangXJ, and TehBT. MicroRNA profiling of human kidney cancer subtypes. Int J Oncol, 35: 109–114, 2009.
118.
PfaffenrothEC and LinehanWM. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther, 8: 779–790, 2008.
119.
PollardPJ, BrièreJJ, AlamNA, BarwellJ, BarclayE, WorthamNC, HuntT, MitchellM, OlpinS, MoatSJ, HargreavesIP, HealesSJ, ChungYL, GriffithsJR, DalgleishA, McGrathJA, GleesonMJ, HodgsonSV, PoulsomR, RustinP, and TomlinsonIP. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet, 14: 2231–2239, 2005.
120.
PothiwalaP, JainSK, and YaturuS. Metabolic syndrome and cancer. Metab Syndr Relat Disord, 7: 279–288, 2009.
121.
RalphSJ, Rodríguez-EnríquezS, NeuzilJ, and Moreno-SánchezR. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med, 31: 29–59, 2010.
122.
RalphSJ, Rodríguez-EnríquezS, NeuzilJ, SaavedraE, and Moreno-SánchezR. The causes of cancer revisited: “mitochondrial malignancy” and ROS-induced oncogenic transformation—why mitochondria are targets for cancer therapy. Mol Aspects Med, 31: 145–170, 2010.
123.
RavalRR, LauKW, TranMG, SowterHM, MandriotaSJ, LiJL, PughCW, MaxwellPH, HarrisAL, and RatcliffePJ. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol, 25: 5675–5686, 2005.
124.
RedovaM, SvobodaM, and SlabyO. MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun, 405: 153–156, 2011.
125.
RickettsCJ, HillVK, and LinehanWM. Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. PLoS One, 9: e85621, 2014.
126.
RönnT and LingC. DNA methylation as a diagnostic and therapeutic target in the battle against Type 2 diabetes. Epigenomics, 7: 451–460, 2015.
127.
RussoI, CosentinoC, Del GiudiceE, BroccolettiT, AmorosiS, CirilloE, AlojG, FuscoA, CostanzoV, and PignataC. In ataxia-teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity. Eur J Neurol, 16: 755–759, 2009.
128.
RzemR, Veiga-da-CunhaM, NoëlG, GoffetteS, NassogneMC, TabarkiB, SchöllerC, MarquardtT, VikkulaM, and Van SchaftingenE. A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria. Proc Natl Acad Sci U S A, 101: 16849–16854, 2004.
SelemidisS, SobeyCG, WinglerK, SchmidtHH, and DrummondGR. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther, 120: 254–291, 2008.
131.
SertznigP, SeifertM, TilgenW, and ReichrathJ. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol, 212: 1–12, 2007.
132.
ShenoyN, VallumsetlaN, ZouY, GaleasJN, ShrivastavaM, HuC, SusztakK, and VermaA. Role of DNA methylation in renal cell carcinoma. Hematol Oncol, 8: 88, 2015.
133.
ShimEH, LiviCB, RakhejaD, TanJ, BensonD, ParekhV, KhoEY, GhoshAP, KirkmanR, VeluS, DuttaS, ChennaB, ReaSL, MishurRJ, LiQ, Johnson-PaisTL, GuoL, BaeS, WeiS, BlockK, and SudarshanS. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov, 4: 1290–1298, 2014.
134.
ShioseA, KurodaJ, TsuruyaK, HiraiM, HirakataH, NaitoS, HattoriM, SakakiY, and SumimotoH. A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem, 276: 1417–1423, 2001.
135.
SolainiG, BaraccaA, LenazG, and SgarbiG. Hypoxia and mitochondrial oxidative metabolism. Biochim Biophys Acta, 1797: 1171–1177, 2010.
136.
SolarekW, CzarneckaAM, EscudierB, BieleckaZF, LianF, and SzczylikC. Insulin and IGFs in renal cancer risk and progression. Endocr Relat Cancer, 22: R253–R264, 2015.
137.
SpectorY, FridmanE, RosenwaldS, ZilberS, HuangY, BarshackI, ZionO, MitchellH, SandenM, and MeiriE. Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas. Mol Oncol, 7: 732–738, 2013.
138.
SudarshanS, SourbierC, KongHS, BlockK, Valera RomeroVA, YangY, GalindoC, MollapourM, ScrogginsB, GoodeN, LeeMJ, GourlayCW, TrepelJ, LinehanWM, and NeckersL. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol, 29: 4080–4090, 2009.
139.
SuhYA, ArnoldRS, LassegueB, ShiJ, XuX, SorescuD, ChungAB, GriendlingKK, and LambethJD. Cell transformation by the superoxide-generating oxidase Mox1. Nature, 401: 79–82, 1999.
140.
SunXZ, VinciC, MakmuraL, HanS, TranD, NguyenJ, HamannM, GrazzianiS, SheppardS, GutovaM, ZhouF, ThomasJ, and MomandJ. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization. Antioxid Redox Signal, 5: 655–665, 2003.
141.
TachibanaK, YamasakiD, IshimotoK, and DoiT. The role of PPARs in cancer. PPAR Res, 2008: 102737, 2008.
142.
TafaniM, SansoneL, LimanaF, ArcangeliT, De SantisE, PoleseM, FiniM, and RussoMA. The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression. Oxid Med Cell Longev, 2016: 3907147, 2016.
143.
TakahashiM, PapaveroV, YuhasJ, KortE, KanayamaHO, KagawaS, BaxterRC, YangXJ, GraySG, and TehBT. Altered expression of members of the IGF-axis in clear cell renal cell Int. carcinoma. J Oncol, 26: 923–931, 2005.
144.
TakamuraT, MisuH, Matsuzawa-NagataN, SakuraiM, OtaT, ShimizuA, KuritaS, TakeshitaY, AndoH, HondaM, and KanekoS. Obesity upregulates genes involved in oxidative phosphorylation in livers of diabetic patients. Obesity, 16: 2601–2609, 2008.
145.
TickooSK, LeeMW, EbleJN, AminM, ChristophersonT, ZarboRJ, and AminMB. Ultrastructural observations on mitochondria and microvesicles in renal oncocytoma, chromophobe renal cell carcinoma, and eosinophilic variant of conventional (clear cell) renal cell carcinoma. Am J Surg Pathol, 24: 1247–1256, 2000.
146.
TomasettiM, SantarelliL, NeuzilJ, and DongL. MicroRNA regulation of cancer metabolism: role in tumour suppression. Mitochondrion, 19: 29–38, 2014.
147.
TrionfiniP, BenigniA, and RemuzziG. MicroRNAs in kidney physiology and disease. Nat Rev Nephrol, 11: 23–33, 2015.
VeluCS, NitureSK, DoneanuCE, PattabiramanN, and SrivenugopalKS. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry, 46: 7765–7780, 2007.
150.
WallaceDC. Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol, 70: 363–374, 2005.
151.
WangHJ, HuangYL, ShihYY, WuHY, PengCT, and LoWY. MicroRNA-146a decreases high glucose/thrombin-induced endothelial inflammation by inhibiting NAPDH oxidase 4 expression. Mediators Inflamm. 379537, 2014.
152.
WARBURGO. On respiratory impairment in cancer cells. Science, 124: 269–270, 1956.
153.
WARBURGO. On the origin of cancer cells. Science, 123: 309–314, 1956.
154.
WendtMK, TianM, and SchiemannWP. Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res, 347: 85–101, 2012.
155.
WhiteNM and YousefGM. MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer. BMC Med, 8: 65, 2010.
156.
WotschofskyZ, MeyerHA, JungM, FendlerA, WagnerI, StephanC, BuschJ, ErbersdoblerA, DischAC, MollenkopfHJ, and JungK. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem, 417: 233–241, 2011.
157.
YanQ, BartzS, MaoM, LiL, and KaelinWGJr.The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol, 27: 2092–2102, 2007.
158.
YanS, LiuG, PeiC, ChenW, LiP, WangQ, JinX, ZhuJ, WangM, and LiuX. Inhibition of NADPH oxidase protects against metastasis of human lung cancer by decreasing microRNA-21. Anticancer Drugs, 26: 388–398, 2015.
159.
YangL, YuanJ, LiuL, ShiC, WangL, TianF, LiuF, WangH, ShaoC, ZhangQ, ChenZ, QinW, and WenW. α-linolenic acid inhibits human renal cell carcinoma cell proliferation through PPAR-γ activation and COX-2 inhibition. Oncol Lett, 6: 197–202, 2013.
160.
YangW, YoshigoeK, QinX, LiuJS, YangJY, NiemierkoA, DengY, LiuY, DunkerA, ChenZ, WangL, XuD, ArabniaHR, TongW, and YangM. Identification of genes and pathways involved in kidney renal clear cell carcinoma. BMC Bioinformatics, 17: S2, 2014.
161.
YangWH, SuYH, HsuWH, WangCC, ArbiserJL, and YangMH. Imipramine blue halts head and neck cancer invasion through promoting F-box and leucine-rich repeat protein 14-mediated Twist1 degradation. Oncogene, 35: 2287–2298, 2016.
162.
YoussefYM, WhiteNM, GrigullJ, KrizovaA, and SamyC, Mejia-GuerreroS, EvansA, and YousefGM. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol, 59: 721–730, 2011.
163.
YueD, ZhangZ, LiJ, ChenX, PingY, LiuS, ShiX, LiL, WangL, HuangL, ZhangB, SunY, and ZhangY. Transforming growth factor-beta1 promotes the migration and invasion of sphere-forming stem-like cell subpopulations in esophageal cancer. Exp Cell Res, 336: 141–149, 2015.
164.
ZhangB, LiuZ, and HuX. Inhibiting cancer metastasis via targeting NAPDH oxidase 4. Biochem Pharmacol, 86: 253–266, 2013.
165.
ZhangL, XulB, ChenS, LuK, LiuC, WangY, ZhaoY, ZhangX, LiuD, and ChenM. The complex roles of microRNAs in the metastasis of renal cell carcinoma. J Nanosci Nanotechnol, 13: 3195–3203, 2013.
166.
ZhangT, NiuX, LiaoL, ChoEA, and YangH. The contributions of HIF-target genes to tumor growth in RCC. PLoS One, 8: e80544, 2013.
167.
ZimmerM, DoucetteD, SiddiquiN, and IliopoulosO. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res, 2: 89–95, 2004.
